Edition:
United Kingdom

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

384.10DKK
20 Sep 2018
Change (% chg)

-- (--)
Prev Close
kr.384.10
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
345,464
52-wk High
kr.477.70
52-wk Low
kr.280.80

Latest Key Developments (Source: Significant Developments)

Lundbeck To Acquire Prexton Therapeutics
Friday, 16 Mar 2018 

March 16 (Reuters) - LUNDBECK ::TO ACQUIRE PREXTON THERAPEUTICS ADDING FOLIGLURAX IN CLINICAL PHASE II TO ITS PIPELINE OF INNOVATIVE TREATMENTS FOR PATIENTS SUFFERING FROM PARKINSON’S DISEASE.‍WILL MAKE AN UPFRONT PAYMENT OF EUR 100 MILLION​.TO ACQUIRE PREXTON THERAPEUTICS ADDING FOLIGLURAX IN CLINICAL PHASE II TO ITS PIPELINE OF INNOVATIVE TREATMENTS FOR PATIENTS SUFFERING FROM PARKINSON’S DISEASE.‍DEAL TERMS ALSO INCLUDE UP TO EUR 805 MILLION​.CONTENT OF THIS RELEASE WILL HAVE NO INFLUENCE ON LUNDBECK'S FINANCIAL GUIDANCE FOR 2018.‍WILL MAKE AN UPFRONT PAYMENT OF EUR 100 MILLION AND DEAL TERMS ALSO INCLUDE UP TO EUR 805 MILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONES​.‍WILL OBTAIN GLOBAL RIGHTS OF FOLIGLURAX​.‍. FIRST DATA FROM ONGOING CLINICAL PHASE II PROGRAMME IS EXPECTED TO BE AVAILABLE DURING FIRST HALF OF 2019.​.‍DEAL TERMS ALSO INCLUDE UP TO EUR 805 MILLION IN DEVELOPMENT, REGULATORY AND SALES MILESTONES​.  Full Article

Lundbeck Says New CEO To Be Named Within Six Months
Wednesday, 7 Feb 2018 

Feb 7 (Reuters) - Lundbeck ::INTERIM CEO GOTZSCHE SAYS EXPECTS NEW CEO WILL BE NAMED WITHIN SIX MONTHS.INTERIM CEO REITERATES THAT HE IS NOT A CANDIDATE FOR THE JOB AS PERMANENT CEO.INTERIM CEO SAYS U.S TAX REFORM MEANS COMPANY WILL SAVE MORE THAN ONE BILLION DANISH CROWNS IN THE COMING FOUR YEARS IN TAXES.INTERIM CEO SAYS EXPECTS IN THE COMING YEARS TO HIRE AROUND 100 NEW EMPLOYEES IN CHINA FROM THE CURRENT LEVEL OF 325-350 EMPLOYEES.  Full Article

Lundbeck: Brintellix Approved In China
Monday, 4 Dec 2017 

Dec 4 (Reuters) - H Lundbeck A/S ::’S BRINTELLIX APPROVED IN CHINA.LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018..  Full Article

Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - H LUNDBECK AS ::LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017 <<>>.‍NOW EXPECTS REVENUE TO REACH DKK 16.9-17.4 BILLION AND EBIT TO REACH DKK 4.3-4.6 BILLION FOR 2017​.‍REVENUE REACHED DKK 12,842 MILLION IN FIRST NINE MONTHS OF 2017​.‍PREVIOUSLY EXPECTED REVENUE OF DKK 16.7-17.5 BILLION AND EBIT OF DKK 4.1-4.5 BILLION​.Q3 REVENUE DKK 4.35‍​ BILLION (REUTERS POLL DKK 4.38 BILLION).Q3 EBIT DKK 1.42‍​ BILLION (REUTERS POLL DKK 1.19 BILLION).  Full Article

Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018.  Full Article

Lundbeck chairman says interim CEO will not become permanent CEO
Tuesday, 31 Oct 2017 

Oct 31 (Reuters) - LUNDBECK CHAIRMAN SAYS:INTERIM CEO GOTZSCHE WILL NOT BECOME PERMANENT CEO FOR LUNDBECK.CERTAIN NEXT CEO WILL BE EXTERNAL CANDIDATE.  Full Article

Lundbeck says Anders Gotzsche to be interim CEO from Nov 1
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Lundbeck - :CHANGES TO LUNDBECK'S EXECUTIVE MANAGEMENT .‍BOARD DECIDED THAT AS OF NOV 1 ANDERS GÖTZSCHE WILL TAKE OVER OPERATIONAL MANAGEMENT OF CO AS INTERIM CEO UNTIL NEW CEO IS IN PLACE​.  Full Article

Otsuka and Lundbeck announce initiation of two phase 3 trials of brexpiprazole in patients with bipolar I disorder
Thursday, 12 Oct 2017 

Oct 12 (Reuters) - Otsuka Holdings Co Ltd <4578.T>:unit Otsuka Pharmaceutical Co., Ltd. and Lundbeck announce that patient enrollment has been initiated in two global Phase 3 clinical trials to evaluate brexpiprazole for the treatment of patients with manic episodes associated with bipolar I disorder.  Full Article

Lundbeck H1 revenue up at DKK 8.49 billion
Wednesday, 9 Aug 2017 

Aug 9 (Reuters) - LUNDBECK ::LUNDBECK REPORTS 13% REVENUE GROWTH AND A DOUBLING OF EBIT IN FIRST HALF OF 2017.REVENUE REACHED DKK 8,494 MILLION IN FIRST SIX MONTHS OF 2017 REPRESENTING AN INCREASE OF 13% COMPARED TO SAME PERIOD LAST YEAR.H1 EPS GREW 186% IN PERIOD TO DKK 6.06 COMPARED TO DKK 2.12 IN SAME PERIOD LAST YEAR.NOW EXPECTS REVENUE TO REACH DKK 16.7-17.5 BILLION AND PROFIT FROM OPERATIONS (EBIT) TO REACH DKK 4.1-4.5 BILLION FOR 2017.  Full Article

Lundbeck: Abilify Maintena (aripiprazole) for extended-release injectable suspension approved by the U.S. FDA for maintenance monotherapy treatment of bipolar I disorder
Friday, 28 Jul 2017 

July 28 (Reuters) - LUNDBECK ::ABILIFY MAINTENA® (ARIPIPRAZOLE) FOR EXTENDED-RELEASE INJECTABLE SUSPENSION APPROVED BY U.S. FDA FOR MAINTENANCE MONOTHERAPY TREATMENT OF BIPOLAR I DISORDER.  Full Article

Photo

European stocks falter as pharma sector falls

LONDON European shares dipped on Wednesday as poor corporate earnings in the pharmaceutical sector weighed on sentiment already soured by trade tensions, with Washington preparing tariffs on another $16 billion (12.4 billion pounds) of Chinese goods.